2010•European Journal of Cancer SupplementsRequires access

81 Potential clinical application of a novel Heat Shock Protein 90 inhibitor CH5164840: preclinical efficacy in mono therapy and combination therapy

Naoki Ono, Osamu Kondoh, Toshikazu Yamazaki, Yohei Nakanishi, Atsushi Suda, Katsuhiko Hada, Reijiro Saito, Toshiyuki Mio, Nobuya Ishii, Yasunobu Aoki

Open publisher page 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Geldanamycin, Hsp90, Heat shock protein, Hsp90 inhibitor, Hsp70, Cancer research, Alpha (finance), Chemistry

Back to paper search Browse research topics Original source

81 Potential clinical application of a novel Heat Shock Protein 90 inhibitor CH5164840: preclinical efficacy in mono therapy and combination therapy — Research Paper | ScholarLens